On October 2, LEADS BIOLABS-B fell 5.24% in regular trading, trading at HK$49.80/share, with turnover of HK$2.4355 million.

The decline occurred amid a broad selloff across the biotechnology sector. Within the sector, BEONE MEDICINES fell 5.86%, 3SBIO fell 5.31%, SKB BIO fell 4.60%, INNOVENT BIO fell 4.28%, and AKESO fell 3.04%, reflecting systemic sector-wide weakness that amplified individual stock declines.

On the company front, LEADS BIOLABS-B had recently announced that its core product LBL-024 received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for the treatment of extrapulmonary neuroendocrine carcinoma — the third such designation following those from the U.S. FDA and the European Commission. Additionally, its pivotal Phase IIb study was selected as a Late-Breaking Abstract at ESMO, with an oral presentation scheduled for October 26. Despite these positive catalysts, the stock has been in a sustained downtrend since reaching a stage high of HK$78.40, with the broader sector headwinds continuing to weigh on price action.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)